These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 8824461)

  • 1. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W; Santen RJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
    Brodie A; Jelovac D; Long BJ
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
    Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
    Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
    J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
    Friedrichs K; Jänicke F
    Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
    Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Lawrence J; MacMahon LP; Yue W; Berstein L
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):155-65. PubMed ID: 16024245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
    Yue W; Zhou D; Chen S; Brodie A
    Cancer Res; 1994 Oct; 54(19):5092-5. PubMed ID: 7923123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitors and breast cancer.
    Brodie AM; Njar VC
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):10-20. PubMed ID: 8824460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
    Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
    Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells.
    Santen RJ; Lobenhofer EK; Afshari CA; Bao Y; Song RX
    Breast Cancer Res Treat; 2005 Dec; 94(3):213-23. PubMed ID: 16258703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.